The Lancet Oncology was launched in September, 2000, as a lively and informative monthly journal covering international issues relevant to clinical cancer specialists worldwide. The journal is now the world-leading clinical oncology periodical publishing high-quality, peer-reviewed research (especially reports from clinical trials), reviews, comment and opinion, weekly news, and Commissions (typically in partnership with societies, governments, NGOs, and academic centres). Content covers topics that advance clinical practice, challenge the status quo, advocate change in health policy, and tackle issues related to global oncology. Much of the journal’s articles are published Online First for enhanced timeliness prior to print publication. Uniquely, all original research is peer-reviewed via a fast-track service, and successful papers are published within 8 weeks of submission. The journal also regularly features podcasts, video, infographics, and curated web content.
In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at controlling the disease's progression. The study, published ...
Apr 5, 2018
0
873
Step off of that bathroom scale. That number won't tell you how healthy you actually are, according to a University of Alberta researcher.
Jan 10, 2020
0
1708
A first-of-its-kind drug targeting a fused gene found in many types of cancer was effective in 93 percent of pediatric patients tested, researchers at UT Southwestern's Simmons Cancer Center announced.
Mar 30, 2018
0
1588
The U.S. Food and Drug Administration yesterday granted accelerated approval to the checkpoint inhibitor Bavencio (avelumab) for the treatment of patients with metastatic Merkel cell carcinoma (MCC), including those who have ...
Mar 24, 2017
0
778
The price of new cancer drugs varies widely (from 28% to 388%) between high-income countries in Europe, Australia, and New Zealand, new research published in The Lancet Oncology has found.
Dec 4, 2015
1
52
A brand new type of cancer drug that acts as a 'Trojan horse' to get inside tumour cells has shown promise in patients with six different cancer types.
Feb 7, 2019
0
720
Women may not need to undergo surgery for non-cancerous ovarian cysts, avoiding potential surgical complications.
Feb 5, 2019
0
392
A combination of two drugs that open the floodgates to an immune system attack on cancer curtailed tumor growth in some patients with non-small cell lung cancer (NSCLC) that was resistant to a single immunotherapy agent, ...
Jan 17, 2022
0
75
One of the world's most popular weed-killers—and the most widely used kind in the U.S.—has been labeled a probable carcinogen by the International Agency for Research on Cancer.
Mar 20, 2015
3
411
A new drug combination for men with advanced prostate cancer has shown sustained increase in survival rates.
Mar 28, 2023
0
17
